05 September 2024
05 September 2024
The TRANSCEND study aims to enrol 100 participants who have not responded to at least four different anti-depressant treatments.
The system offers surgeons the ability to adjust and visualise tension accurately during the repair process.
The proceeds will be used to facilitate the US regulatory approval process and clinical trials for HEPTA's ablation platform.
The FDA has granted de novo Class II classification to the device which uses ultraviolet-C light to disinfect ultrasound probes.
The DaylightRx digital therapeutic delivers cognitive behavioural therapy techniques to patients aged 22 years and above.
Patients using the Dayspring system saw a greater reduction in limb volume and experienced improved quality of life compared to APCDs.
The post-market surveillance study in Europe is running alongside a pivotal trial in the US.
This month: Remote patient monitoring approaches across chronic conditions, the rise of AI in IVF, family offices as a source of MedTech funding, and more.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
